News | December 19, 2025
Ambros Therapeutics launches with $125 million to advance breakthrough therapy for rare pain disorder
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients
The study also showed a clear dose-dependent trend, with the 75 mg QD group outperforming the 50 mg QD cohort
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
The multi-partner team will integrate new technologies across the entire mAb production workflow, from cell line development to purification
The FDA aims to make a decision by April 8, 2026
The companies aim to expand treatment options for millions living with metabolic disorders
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Subscribe To Our Newsletter & Stay Updated
